| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -10.9 | -19.6 |
| EPS (diluted, $ a share) | $-0.14 | $-0.31 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: FULC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Fulcrum Therapeutics, Inc.: key numbers
- Share price
- $3.71Close, Nov 16
- Market cap
- $283M
- Shares outstanding
- 76.38MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Fulcrum Therapeutics, Inc.
All →Fulcrum Therapeutics Signs $7M M&A Deal with Slate Medicines, Inc.
Fulcrum Therapeutics entered into an agreement to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third-party pharmaceutical company for $7.0 million in cash. The sale is a strategic update to its pending merger with Slate Medicines, as the proceeds will be credited to Fulcrum's net cash and are expected to increase the cash dividend declared in connection with the merger.
- Value
- $7M
- Counterparty
- Slate Medicines, Inc.